With increasing competition, the way to gain market share in this quickly growing market is with innovative technology.
Against the odds, Zimmer Biomet is the first company to gain FDA clearance for brain, spine, and knee offerings on one robotic platform.
A study demonstrated that after two years the minimally invasive iFuse procedure was more effective than conservative management.
The Carlsbad, CA-based company said the technology’s initial focus will be on resolving the significant unmet clinical need in minimally invasive lateral procedures, but it can and will be leveraged into multiple Alphatec surgical approaches.
NuVasive has been in the news this week after it was reported that Smith & Nephew was interested in acquiring the company for more than $3 billion. Neither company has officially commented on the rumored deal.
After spending 2018 dealing with quality control remediation and supply chain issues, Zimmer Biomet expects to return to market growth by 2020.
As Zimmer Biomet prepares to enter a surging robotics market, CEO Bryan Hanson said the company wants to make sure the company does it right.
Stryker reported strong performance in the fourth quarter of 2018 with a record number of robots installed and a healthy order book going into 2019.
A $100M joint venture is expected to improve access to advanced rehabilitation technologies for Chinese stroke and spinal cord injury patients.
Co-developed by Medtronic and the recently acquired Mazor Robotics, the system represents a unique marriage between robotics and navigation.
The Warsaw, IN-based company has received clearance for the ROSA Knee System to be used in robotically-assisted total knee replacement procedures.
University of Bristol Medical School Researchers led a study that shows cemented metal-on-plastic hip replacements less than 36 mm in diameter are the most cost-effective in patients older than 65.
Zimmer Biomet is expected to launch a robot soon that will compete with Stryker's Mako Total Knee offering.